For example, the ongoing randomized phase III FIGHT-302 clinical study (NCT03656536)42 is evaluating first-line pemigatinib versus chemotherapy in patients with CCA with FGFR2 rearrangements. This evidence concerns the gene FGFR2 and cholangiocarcinoma.